Quarterly report pursuant to Section 13 or 15(d)

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)

v3.20.2
ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended
Aug. 10, 2020
Mar. 17, 2017
Aug. 25, 2020
Sep. 30, 2020
May 12, 2020
Feb. 18, 2020
Dec. 31, 2019
Dec. 31, 2014
Common stock, par value (in dollars per share) $ 0.0001     $ 0.0001     $ 0.0001  
Common stock, issued 150     638,818     541,816 27,845,000
Common stock, outstanding 150     638,818     541,816 16,000,250
Common stock, authorized       1,000,000,000     1,000,000,000  
Preferred stock, authorized       10,000,000     10,000,000  
Preferred stock, issued       1     1  
Description of shares amendment   On March 17, 2017, the shareholders of the Company approved an amendment to the Company’s Certificate of Incorporation to designate 1 share of the Company’s authorized 10,000,000 shares of Preferred Stock as Series A Preferred Stock (“Series A Preferred Stock”), which shall vote with the Common Stock, and shall be entitled to fifty-one percent (51%) of the total votes of Common Stock on all such matters voted on.            
Reverse stock split ratio of 150:1              
Issuance date Aug. 07, 2020              
Convertible notes payable       $ 1,796,524     $ 1,801,524  
Minimum [Member]                
Common stock, authorized         150,000,000      
Maximum [Member]                
Common stock, authorized         1,000,000,000      
Board Of Directors [Member]                
Common stock, par value (in dollars per share)           $ 0.0001    
Board Of Directors [Member] | Minimum [Member]                
Common stock, authorized           150,000,000    
Board Of Directors [Member] | Maximum [Member]                
Common stock, authorized           1,000,000,000    
Share Exchange Agreement [Member] | Sigyn Therapeutics, Inc [Member]                
Percentage of acquisition ownership interest     100.00%          
Percentage of common stock outstanding     75.00%          
Acquisition date     Oct. 19, 2020          
Convertible notes payable       1,500,000        
Maximum borrwing limit       $ 500,000        
Debt tem       1 year        
Percentage of original issuer discount       10.00%        
Debt conversion price       $ 20        
Acquistion valuation cost       $ 12,500,000        
Description of warrant issued       The noteholders shall receive a five-year warrant to purchase a common share based on a price equal to $30 (based on an approximate Sigyn valuation of $17,500,000.        
Asset Purchase Agreement [Member]                
Cash       $ 100,000